Clinical observation on nedaplatin plus concurrent three-dimensional conformal radiotherapy for advanced esophageal cancer

Document Type

Article

Publication Date

12-1-2010

Abstract

Background: Treatment of esophageal cancer with radiotherapy is not very effective because of local recurrence of cancer. Aims: To investigate the effect and side effects of nedaplatin (NDP) plus concurrent three-dimensional conformal radiotherapy for advanced esophageal cancer. Methods: Seventy-five patients with advanced esophageal cancer confirmed histopathologically were randomly divided into radiotherapy group (37 cases, given conventional radiotherapy of 6 MV-X ray or 15 MV-X ray, 2.0 Gyx5 per week for 6 to 7 weeks) and NDP plus concurrent radiotherapy group (38 cases, additionally given NDP 30-40 mg i.v. once a week for 6 weeks). The short-term effect and short-term side effects were evaluated 3 months after treatment, and long-term effect was recorded and assessed at the end of follow-up. Results: The overall efficacy rate of NDP plus concurrent radiotherapy group was significantly higher than that of radiotherapy group (78.9% vs. 51.4%, P<0.05). There were no significant differences in incidences of 15 grade 2 radiation esophagitis and ≥ grade 3 radiation esophagitis between radiotherapy group and NDP plus concurrent radiotherapy group (40.5% vs. 50.0%, 10.8% vs. 18.4%, P>0.05). The 1-year and 3-year local control rates (73.0% vs. 63.6%, 49.2% vs. 43.3%, P<0.05), and 1-year and 3-year survival rates (69.8% vs. 49.8%, 41.3% vs. 30.2%, P<0.05) of NDP plus concurrent radiotherapy group were significantly higher than those of radiotherapy group. Conclusions: The short-term and long-term effects of NDP plus concurrent radiotherapy are significantly higher than those of radiotherapy, and patients can tolerate its short-term adverse effects, therefore hopefully NDP plus concurrent radiotherapy has the prospect to be used clinically.

Publication Source (Journal or Book title)

Chinese Journal of Gastroenterology

First Page

486

Last Page

488

This document is currently not available here.

Share

COinS